Alterity Therapeutics Ltd Cash Flow Conversion Efficiency
Alterity Therapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, Alterity Therapeutics Ltd (ATHE) has a cash flow conversion efficiency ratio of -0.299x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.80 Million) by net assets ($42.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Alterity Therapeutics Ltd (2002–2026)
Cash flow conversion efficiency of Alterity Therapeutics Ltd from 2002 to 2026. This chart illustrates how Alterity Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ATHE stock price for real-time trading data and today's change.
Alterity Therapeutics Ltd Cash Flow Conversion Ratio Explained
Alterity Therapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Alterity Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alterity Therapeutics Ltd ranked by their cash flow conversion efficiency. Also see Alterity Therapeutics Ltd market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yulho Co. Ltd
KQ:072770
|
-0.042x |
|
Lion One Metals Limited
V:LIO
|
-0.011x |
|
White Pearl Technology Group B
ST:WPTG-B
|
0.057x |
|
Vinyl Group Ltd
AU:VNL
|
-0.277x |
|
Vrancart Adjud
RO:VNC
|
N/A |
|
Access Bio Inc
KQ:950130
|
-0.015x |
|
Goodyear (Thailand) Public Company Limited
BK:GYT
|
0.033x |
|
Kolon Industries Inc
KO:120115
|
0.024x |
Annual Cash Flow Conversion Efficiency for Alterity Therapeutics Ltd (2002–2026)
The table below shows the annual cash flow conversion efficiency of Alterity Therapeutics Ltd from 2002 to 2026. Review ATHE free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $42.73 Million | $-22.03 Million | -0.516x | -90.93% |
| 2025-06-30 | $42.40 Million | $-11.45 Million | -0.270x | +70.44% |
| 2024-06-30 | $13.80 Million | $-12.61 Million | -0.914x | -4.02% |
| 2023-06-30 | $22.81 Million | $-20.04 Million | -0.878x | -152.49% |
| 2022-06-30 | $35.47 Million | $-12.34 Million | -0.348x | +38.84% |
| 2021-06-30 | $30.47 Million | $-17.33 Million | -0.569x | +36.39% |
| 2020-06-30 | $10.55 Million | $-9.43 Million | -0.894x | -6.07% |
| 2019-06-30 | $16.55 Million | $-13.95 Million | -0.843x | -117.06% |
| 2018-06-30 | $16.08 Million | $-6.25 Million | -0.388x | -56.86% |
| 2017-06-30 | $23.69 Million | $-5.87 Million | -0.248x | -4.68% |
| 2016-06-30 | $31.37 Million | $-7.42 Million | -0.237x | +14.91% |
| 2015-06-30 | $39.11 Million | $-10.87 Million | -0.278x | +24.04% |
| 2014-06-30 | $37.69 Million | $-13.79 Million | -0.366x | +35.69% |
| 2013-06-30 | $13.97 Million | $-7.95 Million | -0.569x | +53.26% |
| 2012-06-30 | $5.62 Million | $-6.85 Million | -1.217x | -85.11% |
| 2011-06-30 | $6.93 Million | $-4.56 Million | -0.658x | +26.97% |
| 2010-06-30 | $5.23 Million | $-4.71 Million | -0.900x | +51.72% |
| 2009-06-30 | $3.75 Million | $-6.99 Million | -1.865x | -95.95% |
| 2008-06-30 | $9.89 Million | $-9.41 Million | -0.952x | +41.93% |
| 2007-06-30 | $5.61 Million | $-9.20 Million | -1.639x | -22.82% |
| 2006-06-30 | $8.73 Million | $-11.66 Million | -1.335x | -129.03% |
| 2005-06-30 | $19.51 Million | $-11.37 Million | -0.583x | -321.78% |
| 2004-06-30 | $38.47 Million | $-5.31 Million | -0.138x | +39.11% |
| 2003-06-30 | $15.78 Million | $-3.58 Million | -0.227x | -0.44% |
| 2002-06-30 | $16.68 Million | $-3.77 Million | -0.226x | -- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more